Helsinki, January 2026 — MVision AI today announced that Workspace+ is available for use in New Zealand following notification in the Web-Assisted Notification of Devices (WAND) database. This notification was completed in accordance with local regulatory requirements administered by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).
Workspace+ is a secure, cloud-native AI platform for radiotherapy planning preparation. It is designed to support standardised, guideline-based workflows by reducing variability and promoting consistent quality across radiotherapy planning processes.
Workspace+ serves as the central platform for MVision AI’s growing suite of AI solutions, bringing together:
• Contour+, which assists in producing guideline-based and consistent contours
• Dose+, which generates patient-specific 3D dose predictions
• Image+, which enables synthetic CT generation
• Adapt+, which supports contour propagation between image sets
These AI modules can run independently or as a unified suite, allowing clinics to adopt solutions progressively based on clinical priorities. Workspace+ runs as a DICOM service and integrates directly with treatment planning systems and other DICOM-compliant systems, complementing existing workflows and fitting naturally into daily clinical practice.
“Making Workspace+ available in New Zealand is an important milestone for our platform and for the clinicians and patients it is designed to support,” said Mahmudul Hasan, Founder and CEO of MVision AI. “By automating time-consuming planning tasks, Workspace+ helps clinical teams save time and maintain consistency and quality in treatment planning, supporting more standardised and reproducible, guideline-based planning practices. This supports more efficient use of clinical resources and helps patients receive timely radiotherapy care.”
Workspace+ is distributed in New Zealand by AphaXRT, which acts as the local sponsor. AphaXRT specialises in the distribution, training and support of radiotherapy equipment and software across Australia and New Zealand, helping clinical centres implement and optimise radiation therapy technologies.
This milestone extends MVision AI’s clinical footprint in the region and supports the adoption of AI-powered planning workflows in routine radiotherapy practice across New Zealand.
For more information, visit www.mvision.ai or contact info@mvision.ai.
About MVision AI
Founded in 2017, MVision AI is a Finland-based health technology company developing AI-powered solutions for radiotherapy treatment planning. Its products are used by leading cancer centres worldwide to support faster, more consistent, and patient-specific care across a broad range of clinical workflows.
MVision AI’s mission is to make same-day radiotherapy a reality by providing radiation oncology professionals with intelligent, clinically grounded tools that improve efficiency, support confident decision-making, and help ensure every patient receives high-quality treatment on time.
*CE-marked (CE 2797) medical device under EU MDR 2017/745; this product is not available in all markets.
